Data Insights

Paclitaxel by DAE HWA Pharmaceutical for Metastatic Breast Cancer: Likelihood of Approval

Paclitaxel is under clinical development by DAE HWA Pharmaceutical and currently in Phase II for Metastatic Breast Cancer. According to...

Data Insights

Paclitaxel by Fulgent Pharma for Bile Duct Cancer (Cholangiocarcinoma): Likelihood of Approval

Paclitaxel is under clinical development by Fulgent Pharma and currently in Phase I for Bile Duct Cancer (Cholangiocarcinoma). According to...

Likelihood of Approval and Phase Transition Success Rate Model - Paclitaxel in Bile Duct Cancer (Cholangiocarcinoma)

Data Insights

Paclitaxel by Fulgent Pharma for Recurrent Head And Neck Squamous Cell Carcinoma: Likelihood of Approval

Paclitaxel is under clinical development by Fulgent Pharma and currently in Phase II for Recurrent Head And Neck Squamous Cell...

Likelihood of Approval and Phase Transition Success Rate Model - Paclitaxel in Recurrent Head And Neck Squamous Cell Carcinoma

Data Insights

Paclitaxel by Fulgent Pharma for Oral Cavity (Mouth) Cancer: Likelihood of Approval

Paclitaxel is under clinical development by Fulgent Pharma and currently in Phase II for Oral Cavity (Mouth) Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Paclitaxel in Oral Cavity (Mouth) Cancer

Data Insights

Paclitaxel by Fulgent Pharma for Paranasal Sinus And Nasal Cavity Cancer: Likelihood of Approval

Paclitaxel is under clinical development by Fulgent Pharma and currently in Phase II for Paranasal Sinus And Nasal Cavity Cancer....

Likelihood of Approval and Phase Transition Success Rate Model - Paclitaxel in Paranasal Sinus And Nasal Cavity Cancer

Data Insights

Paclitaxel by Fulgent Pharma for Oropharyngeal Cancer: Likelihood of Approval

Paclitaxel is under clinical development by Fulgent Pharma and currently in Phase II for Oropharyngeal Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Paclitaxel in Oropharyngeal Cancer

Data Insights

Paclitaxel by Fulgent Pharma for Nasopharyngeal Cancer: Likelihood of Approval

Paclitaxel is under clinical development by Fulgent Pharma and currently in Phase II for Nasopharyngeal Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Paclitaxel in Nasopharyngeal Cancer

Data Insights

Paclitaxel by Fulgent Pharma for Laryngeal Cancer: Likelihood of Approval

Paclitaxel is under clinical development by Fulgent Pharma and currently in Phase II for Laryngeal Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Paclitaxel in Laryngeal Cancer

Data Insights

Paclitaxel by Fulgent Pharma for Hypopharyngeal Cancer: Likelihood of Approval

Paclitaxel is under clinical development by Fulgent Pharma and currently in Phase II for Hypopharyngeal Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Paclitaxel in Hypopharyngeal Cancer

Data Insights

Paclitaxel by DAE HWA Pharmaceutical for Metastatic Breast Cancer: Likelihood of Approval

Paclitaxel is under clinical development by DAE HWA Pharmaceutical and currently in Phase II for Metastatic Breast Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Paclitaxel in Metastatic Breast Cancer

Data Insights

Paclitaxel by Samyang Biopharmaceuticals for Esophageal Cancer: Likelihood of Approval

Paclitaxel is under clinical development by Samyang Biopharmaceuticals and currently in Phase II for Esophageal Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Paclitaxel in Esophageal Cancer

Data Insights

Paclitaxel by Samyang Biopharmaceuticals for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval

Paclitaxel is under clinical development by Samyang Biopharmaceuticals and currently in Phase II for Head And Neck Squamous Cell Carcinoma...

Likelihood of Approval and Phase Transition Success Rate Model - Paclitaxel in Head And Neck Squamous Cell Carcinoma (HNSC)

Data Insights

Paclitaxel by Samyang Biopharmaceuticals for Laryngeal Cancer: Likelihood of Approval

Paclitaxel is under clinical development by Samyang Biopharmaceuticals and currently in Phase II for Laryngeal Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Paclitaxel in Laryngeal Cancer

Data Insights

Paclitaxel by Samyang Biopharmaceuticals for Skin Cancer: Likelihood of Approval

Paclitaxel is under clinical development by Samyang Biopharmaceuticals and currently in Phase II for Skin Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Paclitaxel in Skin Cancer

Data Insights

Paclitaxel by Samyang Biopharmaceuticals for Oral Cancer: Likelihood of Approval

Paclitaxel is under clinical development by Samyang Biopharmaceuticals and currently in Phase II for Oral Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Paclitaxel in Oral Cancer

Data Insights

Paclitaxel by PanTher Therapeutics for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval

Paclitaxel is under clinical development by PanTher Therapeutics and currently in Phase I for Pancreatic Ductal Adenocarcinoma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Paclitaxel in Pancreatic Ductal Adenocarcinoma

Data Insights

Paclitaxel by Samyang Biopharmaceuticals for Cervical Cancer: Likelihood of Approval

Paclitaxel is under clinical development by Samyang Biopharmaceuticals and currently in Phase I for Cervical Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Paclitaxel in Cervical Cancer